Categories: CancerNews

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

THE WOODLANDS, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the LSI USA ’25 Emerging Medtech Summit on Tuesday, March 18, 2025 at 7:35 AM PT.

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

The in-person presentation will be accessible to those registered to attend the event. For more information, please visit the conference website.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

Staff

Recent Posts

Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

In this first-of-its-kind partnership for its Dental Solutions business, Solventum, formerly 3M Health Care, is…

3 hours ago

Health in Tech Expands Access to Virtual Care Through Collaboration with DialCare

STUART, Fla., March 25, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform…

9 hours ago

Concord Orthopaedic Notifies Individuals of Security Incident

CONCORD, N.H., March 25, 2025 /PRNewswire/ -- Concord Orthopaedic ("COPA") is an orthopedic clinic located…

9 hours ago

Mitolyn Brand Takes Legal Action Against Third-Party Sellers for Misinformation

HAMPTON, Va., March 25, 2025 /PRNewswire/ -- Bioventra, the parent company and official manufacturer of Mitolyn,…

9 hours ago

THE MOM’S CHOICE AWARDS NAMES AI-POWERED PREGNANCY & BABY WELLNESS WEARABLE ‘ELORA’ AMONG THE BEST IN FAMILY-FRIENDLY PRODUCTS

DOVER, Del., March 25, 2025 /PRNewswire/ -- The Mom's Choice Awards® has named Elora*, from leading…

9 hours ago

Paving the Way for Early Esophageal Cancer Detection:

New Sampling Technique Further Optimizes WATS3D Test Quality SUFFERN, N.Y., March 25, 2025 /PRNewswire/ -- CDx…

9 hours ago